Newsroom

Poster Presented at MICCAI on AI Joint Classification of Images using ⁹⁹ᵐTc-Maraciclatide

A poster was presented today at the annual conference of the Medical Image Computing and Computer Assisted Intervention Society (MICCAI) taking place from 6-10 October in Marrakesh, Morocco. The poster illustrates the latest methodology used in the ongoing research collaboration with King’s College London to develop AI tools to help clinicians read and interpret scans using ^99mTc-maraciclatide.

EANM DETECT Abstract Published and Presentation Details

An abstract on preliminary data from the DETECT “Detecting Endometriosis expressed integrins using technetium-99m” imaging study, has been published ahead of the upcoming congress of the European Association of Nuclear Medicine (EANM).

Phase II PREDICT-ILD Imaging Study Commences in Interstitial Lung Disease

Serac Healthcare Limited and the University of Exeter today announce that the first patient has been scanned with a novel molecular SPECT imaging agent ^99mTc-maraciclatide in a Phase II study titled ‘PRospective Evaluation of Interstitial Lung Disease progression with quantitative CT (PREDICT-ILD)’.

Paper Accepted at MICCAI on AI Joint Classification of Images using ⁹⁹ᵐTc-Maraciclatide

A paper has been accepted for presentation at the annual conference of the Medical Image Computing and Computer Assisted Intervention Society (MICCAI) taking place from 6-10 October in Marrakesh, Morocco.

Abstract Selected as Top Rated Oral Presentation at EANM on DETECT Study Evaluating ⁹⁹ᵐTc-Maraciclatide as a New Imaging Marker for Endometriosis

An abstract on preliminary data from the DETECT “Detecting Endometriosis expressed integrins using technetium-99m” imaging study, has been selected as a Top Rated Oral Presentation at the annual congress of the European Association of Nuclear Medicine (EANM) taking place from 18-23 October 2024 in Hamburg, Germany.

Expanded Access to Medicine Policy

Adopted by the Company on 09 July 2024

Serac Healthcare is dedicated to developing maraciclatide as a new molecular imaging agent that will have a positive impact on patient health, and to serving patients, patient families and patient communities through education, empathy, and awareness.